Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L.

JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642.

PMID:
31454045
2.

Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures.

Zarnegar-Lumley S, Lange KR, Mathias MD, Nakajima-Hatano M, Offer KM, Ogu UO, Ortiz MV, Tan KS, Kellick M, Modak S, Roberts SS, Basu EM, Dingeman RS.

Pediatrics. 2019 Aug;144(2). pii: e20183829. doi: 10.1542/peds.2018-3829.

PMID:
31366683
3.

Extended Sleep Maintains Endurance Performance better than Normal or Restricted Sleep.

Roberts SSH, Teo WP, Aisbett B, Warmington SA.

Med Sci Sports Exerc. 2019 Jun 25. doi: 10.1249/MSS.0000000000002071. [Epub ahead of print]

PMID:
31246714
4.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.

PMID:
30877085
5.

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors.

Ortiz MV, Roberts SS, Glade Bender J, Shukla N, Wexler LH.

Front Oncol. 2019 Feb 26;9:108. doi: 10.3389/fonc.2019.00108. eCollection 2019. Review.

6.

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

Casey DL, Kushner BH, Cheung NV, Modak S, Basu EM, Roberts SS, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):409-414. doi: 10.1016/j.ijrobp.2019.02.004. Epub 2019 Feb 11.

PMID:
30763661
7.

Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.

Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK.

JAMA Oncol. 2018 Dec 1;4(12):1729-1735. doi: 10.1001/jamaoncol.2018.4005.

PMID:
30326045
8.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.

Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC.

Oncoimmunology. 2018 May 10;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305. eCollection 2018.

9.

Effects of training and competition on the sleep of elite athletes: a systematic review and meta-analysis.

Roberts SSH, Teo WP, Warmington SA.

Br J Sports Med. 2019 Apr;53(8):513-522. doi: 10.1136/bjsports-2018-099322. Epub 2018 Sep 14.

PMID:
30217831
10.

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

Fassel H, Bussel JB, Roberts SS, Modak S.

J Pediatr Hematol Oncol. 2019 May;41(4):e257-e259. doi: 10.1097/MPH.0000000000001187.

PMID:
29683946
11.

Treatment and outcome of adult-onset neuroblastoma.

Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S.

Int J Cancer. 2018 Sep 1;143(5):1249-1258. doi: 10.1002/ijc.31399. Epub 2018 Apr 6.

12.

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV.

Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.

13.

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV.

Oncoimmunology. 2017 Jul 31;6(11):e1358331. doi: 10.1080/2162402X.2017.1358331. eCollection 2017.

14.

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.

Modak S, Kushner BH, Basu E, Roberts SS, Cheung NK.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26448. Epub 2017 Jan 23.

15.

Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.

Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, Papaemmanuil E, Ladanyi M, Ku N, Kung AL, Baselga J, Drilon A, Hyman DM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18. No abstract available.

16.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

17.

Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.

Murphy JM, Lim II, Farber BA, Heaton TE, Basu EM, Roberts SS, Modak S, Kushner BH, LaQuaglia MP.

J Pediatr Surg. 2016 Feb;51(2):285-8. doi: 10.1016/j.jpedsurg.2015.10.075. Epub 2015 Nov 5.

18.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

19.

Immunotherapy of Childhood Sarcomas.

Roberts SS, Chou AJ, Cheung NK.

Front Oncol. 2015 Aug 7;5:181. doi: 10.3389/fonc.2015.00181. eCollection 2015. Review.

20.

Osteochondroma in long-term survivors of high-risk neuroblastoma.

Kushner BH, Roberts SS, Friedman DN, Kuk D, Ostrovnaya I, Modak S, Kramer K, Basu EM, Cheung NK.

Cancer. 2015 Jun 15;121(12):2090-6. doi: 10.1002/cncr.29316. Epub 2015 Feb 27.

21.

PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.

Sholler GS, Currier EA, Dutta A, Slavik MA, Illenye SA, Mendonca MC, Dragon J, Roberts SS, Bond JP.

J Cancer Ther Res. 2013 Dec 28;2:21.

22.

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

Cheung NK, Modak S, Ostrovnaya I, Roberts SS, Basu EM, Kramer K, Kushner BH.

J Clin Oncol. 2014 Dec 20;32(36):4173-4. doi: 10.1200/JCO.2014.58.1678. Epub 2014 Nov 17. No abstract available.

PMID:
25403224
23.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

24.

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis T, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, Agnihotri S, Cavalli FM, Clarke I, Nethery-Brokx K, Creasy CL, Verma SK, Koster J, Wu X, Yao Y, Milde T, Sin-Chan P, Zuccaro J, Lau L, Pereira S, Castelo-Branco P, Hirst M, Marra MA, Roberts SS, Fults D, Massimi L, Cho YJ, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Muraszko KM, Kool M, Pomeroy SL, Gupta N, Phillips J, Huang A, Tabori U, Hawkins C, Malkin D, Kongkham PN, Weiss WA, Jabado N, Rutka JT, Bouffet E, Korbel JO, Lupien M, Aldape KD, Bader GD, Eils R, Lichter P, Dirks PB, Pfister SM, Korshunov A, Taylor MD.

Nature. 2014 Feb 27;506(7489):445-50. doi: 10.1038/nature13108. Epub 2014 Feb 19.

25.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Kushner BH, Modak S, Basu EM, Roberts SS, Kramer K, Cheung NK.

Cancer. 2013 Aug 1;119(15):2789-95. doi: 10.1002/cncr.28137. Epub 2013 Apr 30.

26.
27.

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.

Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK.

Bone Marrow Transplant. 2013 May;48(5):642-5. doi: 10.1038/bmt.2012.202. Epub 2012 Oct 22.

PMID:
23085829
28.

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2013 Feb 1;119(3):665-71. doi: 10.1002/cncr.27783. Epub 2012 Sep 5. Review.

29.

Reticulocyte hemoglobin content testing for iron deficiency in healthy toddlers.

Kuehn D, Roberts SS, Olsen CH, Harvey DN, Charnock KM, Brewer BD, Maliakel PG, Lopreiato J.

Mil Med. 2012 Jan;177(1):91-5.

PMID:
22338987
30.

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y, Roberts SS, Massimi L, Van Meter T, Weiss WA, Gupta N, Grajkowska W, Lach B, Cho YJ, von Deimling A, Kulozik AE, Witt O, Bader GD, Hawkins CE, Tabori U, Guha A, Rutka JT, Lichter P, Korshunov A, Taylor MD, Pfister SM.

Cancer Cell. 2011 Aug 16;20(2):143-57. doi: 10.1016/j.ccr.2011.07.007.

31.

Oral administration of a retinoic Acid receptor antagonist reversibly inhibits spermatogenesis in mice.

Chung SS, Wang X, Roberts SS, Griffey SM, Reczek PR, Wolgemuth DJ.

Endocrinology. 2011 Jun;152(6):2492-502. doi: 10.1210/en.2010-0941. Epub 2011 Apr 19.

32.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2010 Nov-Dec;27(6):36, 39. No abstract available.

PMID:
21291149
33.

Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines.

Newton TC, Wolcott K, Roberts SS.

Transl Oncol. 2010 Aug 1;3(4):246-51.

34.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2010 May-Jun;27(3):48-51. No abstract available.

PMID:
20575328
35.

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

Roberts SS, Miller RK, Jones JK, Lindsay KL, Greene MF, Maddrey WC, Williams IT, Liu J, Spiegel RJ.

Birth Defects Res A Clin Mol Teratol. 2010 Jul;88(7):551-9. doi: 10.1002/bdra.20682.

PMID:
20564430
36.

IgG4+ Rosai-Dorfman disease of the lung.

Roberts SS, Attanoos RL.

Histopathology. 2010 Apr;56(5):662-4. doi: 10.1111/j.1365-2559.2010.03519.x. No abstract available.

PMID:
20459580
37.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2010 Mar-Apr;27(2):50-3. No abstract available.

PMID:
20405751
38.

Regulating mitosis and meiosis in the male germ line: critical functions for cyclins.

Wolgemuth DJ, Roberts SS.

Philos Trans R Soc Lond B Biol Sci. 2010 May 27;365(1546):1653-62. doi: 10.1098/rstb.2009.0254. Review.

39.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2010 Jan-Feb;27(1):48-51. No abstract available.

PMID:
20162937
40.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2009 Sep-Oct;26(5):48-51. No abstract available.

PMID:
19873815
41.

What your doctor is reading.

Roberts SS.

Diabetes Self Manag. 2009 Jul-Aug;26(4):69-71. No abstract available.

PMID:
19725403
42.
43.

GABA receptor expression in benign and malignant thyroid tumors.

Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V.

Pathol Oncol Res. 2009 Dec;15(4):645-50. doi: 10.1007/s12253-009-9165-x. Epub 2009 Apr 19.

PMID:
19381877
44.

Lopinavir/ritonavir in pregnancy.

Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):456-61. doi: 10.1097/QAI.0b013e3181a2813f.

PMID:
19381099
45.

Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry.

Roberts SS.

Gastroenterol Nurs. 2008 Nov-Dec;31(6):413-7. doi: 10.1097/SGA.0b013e31818eb70d. Review.

PMID:
19077835
46.

A tricky diagnosis. Why you should learn about celiac disease.

Roberts SS.

Diabetes Forecast. 2008 May;61(5):35-6. No abstract available.

PMID:
18499923
47.

All about your kidneys. Keep them safe, and they will keep you going.

Roberts SS.

Diabetes Forecast. 2008 Mar;61(3):28-9. No abstract available.

PMID:
18446973
49.

Beating the lows. What you need to know about hypoglycemia.

Roberts SS.

Diabetes Forecast. 2008 Feb;61(2):29-30. No abstract available.

PMID:
18354825
50.

Good, bad, and ugly. The inside story of blood lipids and your body.

Roberts SS.

Diabetes Forecast. 2007 Dec;60(13):36-7. No abstract available.

PMID:
18217274

Supplemental Content

Loading ...
Support Center